Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

76.08CHF
20 Apr 2018
Change (% chg)

CHF-1.20 (-1.55%)
Prev Close
CHF77.28
Open
CHF77.12
Day's High
CHF77.14
Day's Low
CHF75.92
Volume
8,440,930
Avg. Vol
5,627,962
52-wk High
CHF88.30
52-wk Low
CHF72.60

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.07
Market Cap(Mil.): CHF207,338.70
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.80
Yield (%): 3.62

Financials

  NOVN.S Industry Sector
P/E (TTM): 23.53 30.65 33.25
EPS (TTM): 3.29 -- --
ROI: 7.52 13.53 13.13
ROE: 11.54 15.22 14.96

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

Apr 20 2018

P&G to buy German Merck's consumer health unit for $4.2 billion

Procter & Gamble Co (P&G) has agreed to acquire Merck KGaA's consumer health unit for 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.

Apr 19 2018

UPDATE 3-P&G to buy German Merck's consumer health unit for $4.2 bln

* Merck to update earnings guidance at Q1 results (Adds Breakingviews link)

Apr 19 2018

BRIEF-Novartis AG CFO Says Q2 Core Operating Profit Growth To Be In Low To Mid Single Digits, Improvements To Come

* CFO SAYS Q2 CORE OPERATING PROFIT GROWTH TO BE IN LOW TO MID SINGLE DIGITS, FOLLOWED BY IMPROVEMENTS LATER IN YEAR

Apr 19 2018

Novartis CEO feels heat on U.S. generics, Cosentyx drop

ZURICH Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.

Apr 19 2018

UPDATE 4-Novartis CEO feels heat on U.S. generics, Cosentyx drop

* Cosentyx sales drop since Q4 worries analysts (Adds comments from CEO, updates shares)

Apr 19 2018

BRIEF-Novartis expects cost cuts, rising Entresto, Cosentyx sales to help meet 2018 op. profit targets

* CEO SAYS BELIEVES COSENTYX SALES FOR FULL YEAR WILL BE IN LINE WITH CONSENSUS, HAD SOME DESTOCKING BY SPECIALTY PHARMA IN Q1 BUT BELIEVES DRUG WILL OVERCOME THAT

Apr 19 2018

UPDATE 3-P&G to buy German Merck's consumer health unit for $4.2 bln

* Merck to update earnings guidance at Q1 results (Adds background on industry, M&A, implications for P&G business)

Apr 19 2018

BRIEF-Novartis AG Says Appoints John Tsai Head Of Global Drug Development And Chief Medical Officer

* SAYS APPOINTS JOHN TSAI HEAD OF GLOBAL DRUG DEVELOPMENT AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Reporting by John Miller)

Apr 19 2018

Novartis Q1 sales beat gets help from weak dollar

ZURICH, April 19 Swiss drugmaker Novartis posted a 10 percent rise in first-quarter sales, more than analysts expected, as new Chief Executive Officer Vas Narasimhan got a boost from a weaker U.S. dollar and rising revenue from new medicines.

Apr 19 2018

Earnings vs. Estimates